Mural Oncology PLC — Investor Relations & Filings

Mural Oncology PLC is a clinical-stage biotechnology company that discovers and develops immunotherapies for cancer treatment. The company leverages its proprietary protein engineering platform to create novel, cytokine-based therapies. Its primary focus is on developing first- and best-in-class drugs for difficult-to-treat tumor types where other immunotherapies, such as checkpoint inhibitors, have not been effective. The company's pipeline is led by nemvaleukin alfa, a novel, engineered IL-2 variant immunotherapy. This candidate is being evaluated in clinical trials for various advanced solid tumors, including platinum-resistant ovarian cancer and advanced melanoma, addressing areas of high unmet medical need.